GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi India Ltd (BOM:500674) » Definitions » EV-to-EBITDA

Sanofi India (BOM:500674) EV-to-EBITDA : 20.62 (As of Mar. 04, 2025)


View and export this data going back to 1991. Start your Free Trial

What is Sanofi India EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sanofi India's enterprise value is ₹114,319 Mil. Sanofi India's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was ₹5,544 Mil. Therefore, Sanofi India's EV-to-EBITDA for today is 20.62.

The historical rank and industry rank for Sanofi India's EV-to-EBITDA or its related term are showing as below:

BOM:500674' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.04   Med: 9.69   Max: 31.26
Current: 13.43

During the past 13 years, the highest EV-to-EBITDA of Sanofi India was 31.26. The lowest was 5.04. And the median was 9.69.

BOM:500674's EV-to-EBITDA is ranked worse than
51.73% of 723 companies
in the Drug Manufacturers industry
Industry Median: 13.17 vs BOM:500674: 13.43

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-03-04), Sanofi India's stock price is ₹5103.05. Sanofi India's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹179.460. Therefore, Sanofi India's PE Ratio (TTM) for today is 28.44.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Sanofi India EV-to-EBITDA Historical Data

The historical data trend for Sanofi India's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi India EV-to-EBITDA Chart

Sanofi India Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.39 6.45 7.13 17.39 29.24

Sanofi India Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.39 18.20 27.59 30.61 -

Competitive Comparison of Sanofi India's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Sanofi India's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi India's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi India's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sanofi India's EV-to-EBITDA falls into.



Sanofi India EV-to-EBITDA Calculation

Sanofi India's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=114319.416/5544
=20.62

Sanofi India's current Enterprise Value is ₹114,319 Mil.
Sanofi India's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,544 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanofi India  (BOM:500674) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Sanofi India's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5103.05/179.460
=28.44

Sanofi India's share price for today is ₹5103.05.
Sanofi India's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹179.460.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Sanofi India EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sanofi India's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi India Business Description

Traded in Other Exchanges
Address
Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is a drug manufacturing company that focuses on a range of therapeutic areas, including Diabetes, Cardiology, Consumer Healthcare, Hospital, Central Nervous System, and Anti-Histamines. The company's diabetes presence includes oral anti-diabetic products and insulin. The consumer healthcare area also maintains a nutraceutical portfolio. The company's export markets include Germany, the U.K., Australia, and Russia. The company utilizes strategic partnerships as a component of its growth.

Sanofi India Headlines

No Headlines